TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1639047
Drug: 500 g
Normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 g salmon daily for 40 days
Study: 6735964
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg daily tobramycin
Study: 6735964
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg daily tobramycin
Study: 6735964
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg daily tobramycin with 1000 mg neomycin
Study: 31766627
Drug: Excessive body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excessive body weight >4000 g
Study: 24527599
Drug: Neurac training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurac training combined with conventional treatments for 2 weeks
Study: 24527599
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments (cervical traction, manual therapy, electrical therapy) for 2 weeks
Study: 22569241
Drug: 130 mg
Normalized name: pectin 130 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 130 mg dehydroepiandrosterone (DHEA)
Study: 20491724
Drug: Zonnic nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zonnic nicotine mouth spray (1 mg/spray)
Study: 20491724
Drug: Zonnic nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zonnic nicotine lozenge (2.5 mg)
Study: 20491724
Drug: Nicorette gum
Normalized name: nicotine Chewing Gum [Nicorette]
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicorette gum (4 mg)
Study: 10354839
Drug: Minimized low-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimized low-weight polypropylene mesh (26.8 g/m2, pore size 5 mm)
Study: 10354839
Drug: Common heavy-weight
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common heavy-weight polypropylene mesh (90.2 g/m2, pore size 0.8 mm)
Study: 7493424
Drug: Topical ouabain
Normalized name: ouabain
DrugBank: Ouabain (DB01092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ouabain
Study: 7493424
Drug: Topical amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical amiloride
Study: 30915963
Drug: Touch-observation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Touch-observation and task-based mirror therapy
Study: 21223512
Drug: Bezafibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (200 mg twice daily)
Study: 21223512
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (1 g twice daily)
Study: 15983318
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (0.4 mg cerivastatin daily, later replaced by 20 mg simvastatin)
Study: 12807387
Drug: Topiramate 600
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 600 mg/day
Study: 12807387
Drug: Topiramate 800
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 800 mg/day
Study: 8649569
Drug: Topiramate 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 1,000 mg/day
Study: 26568588
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg/week
Study: 21176197
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment of malaria in infants (IPTi)
Study: 15650664
Drug: 4-strand semitendinosus/gracilis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-strand semitendinosus/gracilis (ST/G) graft
Study: 15650664
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (BPTB, ST, ST/G)
Study: 12460326
Drug: Prednisolone 20
Normalized name: prednisolone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 20 mg
Study: 12460326
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg
Study: 22490579
Drug: rhNRG‐1 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhNRG‐1 (10 μg·kg‐1·d‐1, I.V.) for 10 days
Study: 22490579
Drug: Sham-operated animals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-operated animals (no treatment)
Study: 20649629
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (evening regimen)
Study: 20649629
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (morning regimen)
Study: 18616492
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of melatonin 60 min before the procedure (group I)
Study: 18616492
Drug: 0.5 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg.kg(‐1) melatonin 60 min before the procedure (group II)
Study: 18616492
Drug: 0.75 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg.kg(‐1) midazolam 15 min before the procedure (group III)
Study: 18616492
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of 0.09 NaCl 15 min (group IV)
Study: 18616492
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of 0.09 NaCl 60 min (group IV)
Study: 16554449
Drug: Etanercept (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (10 mg, 25 mg, 50 mg)
Study: 10553829
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg rapacuronium
Study: 10553829
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg rapacuronium
Study: 10553829
Drug: 0.9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg/kg rapacuronium
Study: 8723577
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 50 to 150 IU/kg SC plus i.v. iron twice weekly for 3 weeks
Study: 1929509
Drug: Ibuprofen 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 0.625 mg/kg
Study: 1929509
Drug: Ibuprofen 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 1.25 mg/kg
Study: 1929509
Drug: Ibuprofen 2.5
Normalized name: hydrocodone-ibuprofen 2.5 mg-200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 2.5 mg/kg
Study: 6135300
Drug: Naloxone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (400 micrograms, 1 ml injection)
Study: 6135300
Drug: Sodium Chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Chloride (0.9%, 1 ml injection)
Study: 29159694
Drug: SDPM-CIP tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDPM-CIP tablets
Study: 29159694
Drug: CIPRO XR®
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIPRO XR® bilayer tablets
Study: 28207527
Drug: Zhibitai 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhibitai 480 mg + atorvastatin 10 mg (ZA10 group)
Study: 28207527
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg (A40 group)
Study: 28207527
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg (A20 group)
Study: 26180243
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g α-GOSs/d
Study: 26180243
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g α-GOSs/d
Study: 26180243
Drug: 18 g
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g α-GOSs/d
Study: 26180243
Drug: Control (glucose
Normalized name: INFINITY CONTROL (GLUCOSE) NORMAL CONTROL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (glucose syrup)
Study: 18322873
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment (endoluminal stenting)
Study: 17725149
Drug: Ginger (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (0.5 gram per capsule, 2 capsules taken one hour before surgery)
Study: 10739506
Drug: Intranasal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal 17beta-estradiol (300 microg/d)
Study: 10739506
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized estradiol (2 mg/d)
Study: 15794392
Drug: Self-Injection Anxiety
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-Injection Anxiety Therapy (SIAT)
Study: 10036345
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 1 mg (4 puffs) plus 2.5 mg nebulized salbutamol
Study: 10036345
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 2.5 mg nebulized salbutamol
Study: 1778084
Drug: Ser-316 suppository
Normalized name: Ser
DrugBank: Serine (DB00133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ser-316 suppository (3 suppositories/week for 6 months)
Study: 371339
Drug: Levomepromazine, 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomepromazine, 12.5 mg
Study: 371339
Drug: Pethidine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine, 50 mg
Study: 31679359
Drug: Fish +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish + Walnut diet (150 g fish and 9 walnuts/week)
Study: 31679359
Drug: Fish diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish diet (300 g/week)
Study: 27913695
Drug: CoQ 2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ 2,400 mg/d
Study: 26291797
Drug: CC plus
Normalized name: STATLOCK PICC PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC plus NAC
Study: 10352387
Drug: CC only
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC only
Study: 26291797
Drug: CC plus
Normalized name: STATLOCK PICC PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC plus metformin
Study: 17577032
Drug: Lomeguatrib (LM)
Normalized name: LM-030
DrugBank: LM-030 (DB18283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomeguatrib (LM) and Temozolomide (TMZ) at doses of 40 to 80 mg LM and 125 mg/m2 TMZ
Study: 17577032
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) at a dose of 200 mg/m2
Study: 11450069
Drug: Neuromuscular Blocking
Normalized name: Neuromuscular blocking agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular Blocking Agents (NBA)
Study: 11450069
Drug: No Neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Neuromuscular Blocking Agents (Control)
Study: 9349334
Drug: Topical doxepin
Normalized name: doxepin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical doxepin
Study: 7909999
Drug: Oral terfenadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terfenadine
Study: 8451599
Drug: Glucagon infusion
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon infusion (5 ng kg‐1 min‐1)
Study: 29144812
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical therapy (IMT; n = 25)
Study: 24571582
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of leuprolide acetate injections (Group A)
Study: 24571582
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of leuprolide acetate injections (Group B)
Study: 19462276
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FNA) 3 mg IV weekly
Study: 19462276
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 1 mg IV weekly
Study: 19462276
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of folinic acid and vitamin B12 IV weekly
Study: 7707099
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride 10 mg orally
Study: 7707099
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride 10 mg rectally
Study: 780062
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (oral solution)
Study: 780062
Drug: Oxytocin (buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (buccal tablets)
Study: 30277102
Drug: Obinutuzumab plus
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab plus CHOP (G-CHOP)
Study: 30277102
Drug: Shorter duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter duration of infusion (SDI) of obinutuzumab
Study: 21121874
Drug: omalizumab (75-375
Approvals — FDA: no, EMA: no, PMDA: no
Description: omalizumab (75-375 mg sc, q2 or q4 wk)
Study: 17491173
Drug: NOT Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOT Plus (Web-based adjunct)
Study: 15307288
Drug: Magnetostimulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetostimulation with weak variable magnetic field (15 microT) for 12 minutes daily for 15 days added to pharmacological therapy.
Study: 11713611
Drug: Buspirone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (0.5 mg x kg bw(‐1) orally)
Study: 11713611
Drug: Buspirone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone with pindolol pre‐treatment (40 mg over 2 days, 0.5 mg x kg bw(‐1) on test day)
Study: 11713611
Drug: Pindolol alone
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol alone (40 mg over 2 days)
Study: 11713611
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with pindolol pre‐treatment
Study: 24622804
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (2000 IU oral vitamin D3/d)
Study: 20083429
Drug: Standard CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CPAP titration during polysomnography (PSG)
Study: 20083429
Drug: Ambulatory titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory titration using auto‐CPAP and home sleep testing
Study: 18812608
Drug: BI 1356
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1356 (2.5 mg)
Study: 18812608
Drug: BI 1356
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1356 (5 mg)
Study: 18812608
Drug: BI 1356
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1356 (100 mg to 600 mg)
Study: 18812608
Drug: BI 1356
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1356 (600 mg)
Study: 6423016
Drug: Capsaicin inhalation
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin inhalation (2-65 mumol l(-1), 1 min duration)
Study: 810270
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate inhalation
Study: 20810517
Drug: Treatment arms
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arms
Study: 25462877
Drug: Enhanced cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced cognitive behavior therapy (CBT-E)
Study: 23270535
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (two different doses)
Study: 6403323
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg ergotamine tartrate
Study: 6403323
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg ergotamine tartrate
Study: 24836213
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg daily for three months
Study: 18418029
Drug: Desloratadine (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine (standard dose) during association phase
Study: 18418029
Drug: Novel-tasting drink
Normalized name: 60 Second Taste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel-tasting drink with placebo pill (CS group) during evocation trial
Study: 18418029
Drug: Water with
Normalized name: sterile water with electrolytes injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water with desloratadine (drug group) during evocation trial
Study: 12888045
Drug: Topical betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betaxolol (twice daily)
Study: 8917061
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride 300 mg twice daily for 14 days
Study: 1869343
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg diphenhydramine
Study: 26998485
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser plus topical application of Botulinum Toxin Type A (BTX‐A)
Study: 26998485
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 plus saline solution
Study: 26998485
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (BTX‐A and saline solution)
Study: 17413119
Drug: 10.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.5 g P. ovata husk/d
Study: 17413119
Drug: 10.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.5 g P. ovata seeds/d
Study: 12882179
Drug: Weights over
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weights over 1,500 g
Study: 12882179
Drug: Weights <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weights < 1,500 g
Study: 7588510
Drug: High-fibre diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fibre diet based on oat bran (31.9 g/day fibre)
Study: 7588510
Drug: Low-fibre diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fibre diet based on wheat flour (7.8 g/day fibre)
Study: 6999828
Drug: Ketocaine compresses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketocaine compresses (1 g ketocaine in a 10% ethanol solution)
Study: 25742716
Drug: Standard-dose GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose GH treatment (33 μg kg(‐1) day(‐1))
Study: 25742716
Drug: Double-dose treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose treatment (67 μg kg(‐1) day(‐1))
Study: 19798097
Drug: Diuretics as
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics as component of therapy
Study: 19798097
Drug: Renin system
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin system inhibitors
Study: 16117967
Drug: CQ +
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CQ + AS (4 mg/kg bodyweight daily for 3 days)
Study: 16117967
Drug: CQ (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQ (25 mg/kg bodyweight over 3 days)
Study: 10836728
Drug: Manidipine (M)
Normalized name: manidipine
DrugBank: Manidipine (DB09238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine (M) 10-20 mg, od, for 24 weeks
Study: 10836728
Drug: Enalapril (E)
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril (E) 10-20 mg, od, for 24 weeks
Study: 9376779
Drug: bromocriptine 25
Normalized name: bromocriptine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromocriptine 25 mg
Study: 9376779
Drug: bromocriptine 50
Normalized name: bromocriptine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromocriptine 50 mg
Study: 1317178
Drug: Scopolamine (0.002,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.002, 0.004, and 0.007 mg/kg)
Study: 1317178
Drug: Intramuscular glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular glycopyrrolate (0.0044 mg/kg)
Study: 3910428
Drug: Droperidol 2.5
Normalized name: droperidol 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 2.5 mg i.m. before anaesthesia
Study: 3910428
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg i.v. at the end of anaesthesia
Study: 30201408
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg BMS-986020 (bid)
Study: 30201408
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg BMS-986020 (qd)
Study: 27139158
Drug: Pregabalin 450
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 450 mg/d
Study: 25985851
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one capsule of placebo per day)
Study: 21600390
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (generic Mycophenolate mofetil 500 mg)
Study: 21600390
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (branded Mycophenolate mofetil 500 mg)
Study: 19713965
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg daily)
Study: 16449345
Drug: SR 49059
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 49059 (200 mg once daily)
Study: 15033935
Drug: Oral tertatolol
Normalized name: tertatolol
DrugBank: Tertatolol (DB13775)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tertatolol (nonselective beta-antagonist) treatment during exercise bouts at 35% and 60% peak oxygen consumption (VO2max)